Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Blinatumomab for Minimal Residual Disease Before Hematopoietic Stem Cell Transplantation With Pediatric B-cell Precursor Acute Lymphoblastic Leukemia

NCT04604691 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT04604691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04604691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Blinatumomab for Minimal Residual Disease Before Hematopoietic Stem Cell Transplantation With Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
Lead sponsor
Seoul National University Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
February 18, 2022
Completion date
December 31, 2024
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

minimal residual disease, pediatric all, b cell